Intergel Side Effects

Zimmerman Reed is investigating serious injuries that may have resulted from a product that had been used to reduce internal scarring after gynecological surgery. The product, Intergel, was developed and sold by Lifecore Biomedical, Inc. of Chaska Minnesota and was marketed by Johnson & Johnson’s Gynecare unit. On March 27, 2003, Lifecore announced it was voluntarily withdrawing Intergel from the market and suspending global sales to assess information obtained from postmarketing experience with the product.

In addition, Lifecore’s marketing partner, Gynecare, sent a letter to physicians dated March 28, 2003 stating they had received reports of problems including late-onset, post-operative pain and repeat surgeries following onset pain. The FDA reports 72 “adverse events,” including 3 deaths and 48 injuries among U.S. patients treated with Intergel.

The FDA initially rejected the Gynecare Intergel in 2000, concluding that administering the gel increased a woman’s risk of infection. Lifecore appealed the denial and in November 2001 the product was approved. Upon approval, the FDA called the use of Intergel only “reasonably safe.”

If you would like to complete a confidential free case review detailing specific injuries you experienced that you believe are related to your use of Intergel, please click here. If you do not wish to submit information online, and would like legal counsel regarding serious injuries associated with this Intergel, we encourage you to contact attorney Ronald S. Goldser toll-free at 1.800.755.0098.